Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.

BACKGROUND The purpose of the study was to characterize histological response to chemotherapy of hepatic colorectal metastases (HCRM), evaluate efficacy of different chemotherapies on histological response, and determine whether tumor regression grading (TRG) of HCRM predicts clinical outcome. PATIENTS AND METHODS TRG was evaluated on 525 HCRM surgically resected from 181 patients, 112 pretreated with chemotherapy. Disease-free survival (DFS) and overall survival (OS) were correlated to TRG. RESULTS Tumor regression was characterized by fibrosis overgrowing on tumor cells, decreased necrosis, and tumor glands (if present) at the periphery of HCRM. With irinotecan/5-fluorouracil (5-FU), major (MjHR), partial (PHR), and no (NHR) histological tumor regression were observed in 17%, 13%, and 70% of patients, respectively. With oxaliplatin/5-FU, MjHR, PHR, and NHR were observed in 37%, 45%, and 18% of patients, respectively. Five patients, treated with oxaliplatin, had complete response in all their metastases. MjHR was associated with an improved 3-year DFS compared with PHR or NHR. MjHR and PHR were associated with an improved 5-year OS compared with NHR. CONCLUSION Histological tumor regression of HCRM to chemotherapy corresponds to fibrosis overgrowth and not to increase of necrosis. TRG should be considered when evaluating efficacy of chemotherapy for HCRM. Histological tumor regression was most common among oxaliplatin-treated patients and associated with better clinical outcome.

[1]  M. Ducreux,et al.  Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy , 2004, Journal of surgical oncology.

[2]  D. Sargent,et al.  Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  B. Siegel,et al.  Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET) , 2004, Annals of surgery.

[4]  Michael A. Choti,et al.  Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases , 2002, Annals of surgery.

[5]  J. Ajani,et al.  Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E F Halpern,et al.  Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. , 2001, Radiology.

[7]  R. Goldberg,et al.  Systemic therapy for metastatic colorectal cancer: current options, current evidence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Morel,et al.  Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.

[9]  Evelyne M. Loyer,et al.  Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.

[10]  P. Coucke,et al.  Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy , 2002, Cancer.

[11]  G. Kroemer,et al.  Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA , 2004, Oncogene.

[12]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Mark A. Helvie,et al.  Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy , 2005, Breast Cancer Research and Treatment.

[14]  V. Bramwell.  The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. , 1997, Seminars in oncology.

[15]  N. Kemeny,et al.  Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[17]  M. Espié,et al.  Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. , 2005, Oncology reports.

[18]  Catherine Julié,et al.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Rubbia‐Brandt,et al.  Results of inverse strategy using systemic chemotherapy (CT) first, liver resection second, and primary tumor resection last for patients with advanced synchronous liver metastases (ASLM) from colorectal cancer (CRC) , 2005 .

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[22]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[23]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[24]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[25]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[26]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Bonadonna,et al.  Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  D. Sargent,et al.  Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Bioulac-Sage,et al.  Impact of Colloid Response on Survival After Preoperative Radiotherapy in Locally Advanced Rectal Carcinoma , 2005, The American journal of surgical pathology.

[30]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.